* B.A., Sociology, University of Virginia, 1969
* M.S., Biostatistics, University of North Carolina, Chapel Hill, 1987
* Ph.D., Biostatistics, University of North Carolina, Chapel Hill, 1989
Application of biostatistical methods to support clinical research in schizophrenia.
Hong LE, Turano KA, O'Neill H, Hao L, Wonodi I, McMahon RP, Elliot A, Thaker GK. Refining the predictive pursuit endophenotype in schizophrenia. In press, Biological Psychiatry, 2007
Arango C, McMahon RP,Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan RW,. Patterns of cranial, brain and sulcal CSF. In press, Psychiatry Research: Neuroimaging.
Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP. Metabolic risk with second generation antipsychotic treatment: Results from a double-blind randomized 8-week trial of risperidone and olanzapine. In press,Annals of Clinical Psychiatry, 2007.
Buchanan RW, Javitt D, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT, The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive Impairments. In press. Am J Psychiatry, 2007.
Heerey EA, Robinson B, McMahon RP, Gold JM, Delay discounting in schizophrenia, Cognitive Neuropsychiatry, 2007; 12:213-21.
Dorgan JF, McMahon RP, Friedman LA, Van Horn L, Snetselaar LG, Kwiterovich PO, Lauer RM, Lasser NL, Stevens VJ, Robson A, Cooper SF, Chandler DW, Franklin FA, Barton BA, Patterson BH, Taylor PR, Schatzkin A. Diet and sex hormones in boys: Findings from the Dietary Intervention Study in Children. 2006 Oct;91(10):3992-6.
Saperstein AM, Fuller RL, Avila MT, Adami H, McMahon RP, Thaker GK, Gold JM. Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull. 2006; 32:498 506..
Gold JM, Fuller RL, Robinson B, McMahon RP, Braun E and Luck S. Intact attentional control of working memory encoding in schizophrenia. J Abnorm Psychol. 2006 Nov;115(4):658-73.
Fuller RL, Luck SJ, Braun EL, Robinson B, McMahon RP, Gold JM. Impaired control of visual attention in schizophrenia. J Abnormal Psychology, 2006; 115:266-75.
Kimm SY, Glynn NW, McMahon RP, Voorhees CC, Striegel-Moore RH, Daniels SR. Self-perceived barriers to activity participation among sedentary adolescent girls. Med Sci Sports Exerc, 2006; 38:534 540.
Hong LE, Mitchell BD, Avila MT, Adami H, McMahon RP, Thaker GT, Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch Gen Psychiatry; 2006: 63:259 64.
Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatric Quarterly, 2006;77(1):81 95.
Lahti AC, Weiler MA., Holcomb HH, Tamminga CA., Carpenter WT, McMahon R. Correlations between rCBF and symptoms in two independent cohorts of drug free patients with schizophrenia. Neuropsychopharmacology. 2006; 31:221 30.
Wilk CM, Gold JM, McMahon RP, Humber K, Iannone VN, Buchanan RW, No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology, 2005, 19:778 86.
Conley RR, Shim JC, Kelly DL, Feldman S, Yu Y, McMahon RP., Cardiovascular disease in relation to weight in deceased persons with schizophrenia. Compr Psychiatry, 2005: 46:460 7..
Hong LE, Avila MT, Wonodi I, McMahon RP, Thaker GK, Reliability of a portable head-mounted eye tracking device for schizophrenia research. Behavior Research Methods, Instruments, and Computers , 2005: 37: 133-138.
Hong LE, Wonodi I, Avila MT, Buchanan RW, McMahon RP, Mitchell BD, Stine OC, Carpenter Jr. WT, Thaker GK. Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. Am J Medical Genetics Part B: Neuropsychiatric Genetics, 2005; 136:8-11.
Fuller RLM, McMahon RP, Luck SJ and Gold JM. Working memory consolidation is abnormally slow in schizophrenia. J Abnormal Psych, 2005; 114(2):279 90.
Kim CK, McGorray SP, Bartholomew BA, Marsh M, Dicken T, Wassertheil-Smoller S, Curb JD, Oberman A, Hsia J, Gardin J, Wong ND, Barton B, McMahon RP, Sheps DS, Depressive symptoms and heart rate variability in postmenopausal women. Arch Intern Med. 2005;165:1239
McMahon RP, Arndt S, Conley RR. More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk. Statistics in Medicine, 2005, 24:11
Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold J, McMahon RP, Carpenter WT. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry, 2005, 162:124 9
Franko DL, Striegel-Moore RH, Brown KM, Barton BA, McMahon RP, Schreiber GB, Crawford PB, and Daniels SR. Expanding understanding of the relationship between negative life events and depressive symptoms in black and white adolescent girls. Psychol Med, 2004; 34:1319-30.
Hong LE, Summerfelt A, McMahon R, Adami H, Francis G, Elliott A, Thaker GK, Buchanan RW. Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res, 2004; 70:293-302.
Holcomb HH, Parwani A, McMahon RP, Medoff DR, Frey K, Lathi AC, Tamminga CA. Parametric study of accuracy and response time in schizophrenic persons making visual or auditory discriminations. Psychiatry Research 2004; 127:307-217.
Zanjani H, Lemaigre-Dubreuil Y, Tillakaratne NK, Blokhin A, McMahon RP, Tobin AJ, Vogel MW and Mariani J. Cerebellar purkinje cell loss in aging Hu-Bcl-2 transgenic mice. J Comp Neurol, 2004:475:481-492.
Hong LE, Summerfelt A, McMahon RP, Thaker GK, Buchanan RW. Gamma/beta oscillationand sensory gating deficit in schizophrenia. Neuroreport, 2004; 15:155-9.
Joy B, McMahon RP, Shepard PD. Effects of acute and chronic clozapine on d-amphetamine-induced disruption of auditory gating in the rat. Psychopharmacology, 2004;174:274-282.
Kelly DL, Love RC, Mackowick M, McMahon RP, Conley RR. Atypical antipsychotic use in a state-hospital inpatient adolescent population. J Child Adolesc Psychopharmacology, 2004; 14:75-85.
Buchanan, RW, Francis A. Arango C, Miller K, Lefkowtiz D, McMahon RP, Barta PE , Pearlson GD. Morphometric asessment of the heteromodal cortex in schizophrenia. Am J Psychiatry. 2004; 161:322
Avila MT, Adami HM, McMahon RP, Thaker GK. Using neurophysiological markers of genetic risk to define the boundaries of the schizophrenia spectrum phenotype Schizophr Bull. 2003;29(2):299 309.
Arango C, Breier A, McMahon R, Carpenter WT, Buchanan RW, The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiary, 2003; 160:1421-1427.
Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Annals of Clinical Psychiatry, 2003;15:23-31.
Gold JM, Wilk CP, McMahon RP, Buchanan RW, Luck SJ. Working memory for visual features and conjunctions in schizophrenia. J Abnormal Psych 2003; 112:61-71.
Baymiller S, Buchanan RW, McMahon RP. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic anatgonist treatment. Schizophr Res 2003; 59:49-57.
Adami H, Elliott A, Zetlmeisl M, McMahon R, Thaker G. Use of telephone screens improves efficiency of healthy subject recruitment. Psychiatry Res 2002; 113(3):295 301
Kimm SY, Barton BA, Obarzanek E, McMahon RP, Kronsberg SS, Waclawiw MA, Morrison JA, Schreiber GB, Sabry ZI, Daniels SR. Obesity Development DuringAdolescence in a Biracial Cohort: The NHLBI Growth and Health Study. Pediatrics 2002;110(5):E54 E54 (www.pediatrics.org/cgi/ content/full/110/5/e54)
Baymiller SP, Ball P, McMahon RP, Buchanan RW. Weight and blood pressure change during clozapine therapy. Clin. Neuropharmacology, 2002; 25:202-6.
Avila MT, McMahon RP, Elliott AR, Thaker GT. Neurophysiological Markers of Vulnerability to Schizophrenia: Sensitivity and Specificity of Specific Quantitative Eye Movement Measures. J Abnormal Psych, 2002; 111:259-67.
Sheps DS, McMahon RP, Becker L, Carney RM, Freedland KE, Cohen JD, Sheffield D, Goldberg AD, Ketterer MW, Pepine CJ, Raczynski JM, Light K, Krantz DS, Stone PH, Knatterud GL, Kaufmann PG. Mental stress induced ischemia and all cause mortality in patients with coronary artery disease: results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation, 2002;105(15): 1780 4
McMahon RP, Kreyenbuhl J, Kirkpatrick B, Kelly D, Love RC, Conley R. Novel Factor-Based Symptom Scores in Treatment Resistant Schizophrenia: Implications for Clinical Trials. Neuropsychopharmacology, 2002; 537-545.
Tek C, Gold J, Blaxton T, Wilk C, McMahon RP, Buchanan RW. Visual perception and working memory impairments in schizophrenia. Arch Gen Psychiatry, 2002; 59:146-53..
Kimm SYS, Barton BA, Obarzanek E, McMahon RP, Sabry ZI, Waclawiw MA, Schrieber GB, Morrison JA, Similo S, Daniels SR. Racial divergence in adiposity during adolescence: The NHLBI Growth and Health Study. Pediatrics, 2001; 107:e.34 (www.pediatrics.org/cgi/ content/full/103/3/e34)
Striegel-Moore RH, McMahon RP, Biro FM, Schreiber GB, Crawford PB, Exploring the relationship between timing of menarche and eating disorder symptoms in black and white adolescent girls: The NHLBI Growth and Health Study. International Journal of Eating Disorders, 2001; 30:421-433.
Proschan M A, McMahon RP, Shih JH, Hunsberger SA, Geller NL, Knatterud G and Wittes J. Sensitivity analysis using an imputation method for missing binary data in clinical trials. J Stat Planning and Inference, 2001;96:155-165.
McMahon RP and Harrell FE. Joint testing of mortality and a non-fatal outcome in clinical trials. Statistics in Medicine, 2001; 20:1214-1234.
McMahon RP and Harrell FE. Power calculations for clinical trials when the outcome is a composite ranking of survival and a nonfatal outcome. Controlled Clinical Trials, 2000; 21:305-312.
McMahon RP, Waclawiw MA, Geller NL, Barton FB, Terrin ML and Bonds DR. An extension of stochastic curtailment for incompletely reported and classified recurrent events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). Controlled Clinical Trials, 1997; 18:420-30.
McMahon RP, Proschan M, Geller NL, Stone PH and Sopko G. Sample size calculation for clinical trials in which entry criteria and outcomes are counts of events. Statistics in Medicine, 1994; 13:859-70.